OS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSE:OSTX - Free Report) in a report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $20.00 price objective on the stock.

Separately, Maxim Group began coverage on OS Therapies in a research report on Tuesday, November 26th. They set a "buy" rating and a $8.00 price objective on the stock.

OS Therapies Trading Down 5.5 %

Shares of NYSE OSTX traded down $0.24 during mid-day trading on Wednesday, hitting $4.12. 579,063 shares of the company's stock traded hands, compared to its average volume of 2,004,922. OS Therapies has a 1 year low of $1.58 and a 1 year high of $7.00. The business has a 50-day moving average of $3.29.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new stake in OS Therapies Inc (NYSE:OSTX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,045 shares of the company's stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.